Literature DB >> 23416982

MiR-155 at the heart of oncogenic pathways.

M F Czyzyk-Krzeska1, X Zhang2.   

Abstract

MicroRNAs are increasingly being recognized as oncogenes and tumor suppressors in cancer. MicroRNA-155 (miR-155) is an established oncomiR in breast cancer and regulates several pro-oncogenic pathways. In light of this, Chiang's group has discovered a novel pathway regulated by miR-155. MiR-155 directly targets the VHL tumor suppressor and, by doing so, promotes the activity of HIF transcription factors and angiogenesis. This pathway appears to be particularly relevant in triple-negative breast cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23416982      PMCID： PMC4047641          DOI： 10.1038/onc.2013.26

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  12 in total

1.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene.

Authors:  Shuai Jiang; Hong-Wei Zhang; Ming-Hua Lu; Xiao-Hong He; Yong Li; Hua Gu; Mo-Fang Liu; En-Duo Wang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

2.  Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Authors:  Suhwan Chang; Rui-Hong Wang; Keiko Akagi; Kyung-Ae Kim; Betty K Martin; Luca Cavallone; Diana C Haines; Mark Basik; Phuong Mai; Elizabeth Poggi; Claudine Isaacs; Lai M Looi; Kein S Mun; Mark H Greene; Stephen W Byers; Soo H Teo; Chu-Xia Deng; Shyam K Sharan
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

3.  MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia.

Authors:  Ulrike Bruning; Luca Cerone; Zoltan Neufeld; Susan F Fitzpatrick; Alex Cheong; Carsten C Scholz; David A Simpson; Martin O Leonard; Murtaza M Tambuwala; Eoin P Cummins; Cormac T Taylor
Journal:  Mol Cell Biol       Date:  2011-08-01       Impact factor: 4.272

4.  MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.

Authors:  William Kong; Lili He; Marc Coppola; Jianping Guo; Nicole N Esposito; Domenico Coppola; Jin Q Cheng
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.

Authors:  Imran A Babar; Jennifer Czochor; Allison Steinmetz; Joanne B Weidhaas; Peter M Glazer; Frank J Slack
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

7.  A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells.

Authors:  Shuai Jiang; Ling-Fei Zhang; Hong-Wei Zhang; Song Hu; Ming-Hua Lu; Sheng Liang; Biao Li; Yong Li; Dangsheng Li; En-Duo Wang; Mo-Fang Liu
Journal:  EMBO J       Date:  2012-02-21       Impact factor: 11.598

8.  MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.

Authors:  William Kong; Hua Yang; Lili He; Jian-jun Zhao; Domenico Coppola; William S Dalton; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

9.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Authors:  Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

10.  Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer.

Authors:  W Kong; L He; E J Richards; S Challa; C-X Xu; J Permuth-Wey; J M Lancaster; D Coppola; T A Sellers; J Y Djeu; J Q Cheng
Journal:  Oncogene       Date:  2013-01-28       Impact factor: 9.867
View more
  26 in total

1.  Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt's lymphoma exosomes.

Authors:  Changshin Yoon; Jayoung Kim; Gabin Park; Seonghan Kim; Daejin Kim; Dae Young Hur; Bomi Kim; Yeong Seok Kim
Journal:  Tumour Biol       Date:  2015-07-26

2.  Effect of nitric oxide on microRNA-155 expression in human hepatic epithelial cells.

Authors:  Yael Yuhas; Eva Berent; Shai Ashkenazi
Journal:  Inflamm Res       Date:  2014-04-01       Impact factor: 4.575

Review 3.  Role of miR-155 in the regulation of lymphocyte immune function and disease.

Authors:  Nabila Seddiki; Vedran Brezar; Nicolas Ruffin; Yves Lévy; Sanjay Swaminathan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 4.  Small molecule compounds targeting miRNAs for cancer therapy.

Authors:  Paloma Del C Monroig; Lu Chen; Shuxing Zhang; George A Calin
Journal:  Adv Drug Deliv Rev       Date:  2014-09-17       Impact factor: 15.470

5.  Expression of microRNA-155 in inflammatory cells modulates liver injury.

Authors:  Delia Blaya; Beatriz Aguilar-Bravo; Fengjie Hao; Silvia Casacuberta-Serra; Mar Coll; Luis Perea; Júlia Vallverdú; Isabel Graupera; Elisa Pose; Laura Llovet; Jordi Barquinero; Francisco Javier Cubero; Juan Caballería; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2018-05-02       Impact factor: 17.425

6.  Overexpression of HIF-1α protects PC12 cells against OGD/R-evoked injury by reducing miR-134 expression.

Authors:  Hongliang Zhang; Xianming Liu; Fengyu Yang; Dekui Cheng; Wei Liu
Journal:  Cell Cycle       Date:  2020-04-08       Impact factor: 4.534

7.  miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway.

Authors:  Taichi Isobe; Shigeo Hisamori; Daniel J Hogan; Maider Zabala; David G Hendrickson; Piero Dalerba; Shang Cai; Ferenc Scheeren; Angera H Kuo; Shaheen S Sikandar; Jessica S Lam; Dalong Qian; Frederick M Dirbas; George Somlo; Kaiqin Lao; Patrick O Brown; Michael F Clarke; Yohei Shimono
Journal:  Elife       Date:  2014-11-18       Impact factor: 8.140

8.  MicroRNA-155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1.

Authors:  Zhijun Ma; Yulan Ma; Qinghua Xia; Yong Li; Ruidong Li; Weilong Chang; Jinhuang Chen; Zhengwei Leng; Kaixiong Tao
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-08       Impact factor: 4.553

Review 9.  MicroRNAs in multiple myeloma and related bone disease.

Authors:  Marco Rossi; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Ann Transl Med       Date:  2015-12

10.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.